Medtronic on Jan. 21 released three-month results from a clinical trial highlighting the effectiveness of Differential Target Multiplexed spinal cord stimulation in treating back pain, compared to traditional SCS.
Four insights:
1. The study found that 80 percent of patients suffering from chronic back pain and treated with DTM reported at least 50 percent pain relief, compared with 51 percent of patients treated with traditional SCS.
2. Sixty-three percent of patients treated with DTM reported pain relief of 80 percent or greater, compared to 26 percent treated with traditional SCS.
3. Administered via Medtronic's Intellis platform, DTM SCS therapy is a programming option used to treat patients with chronic pain.
4. DTM was developed by Stimgenics, which was acquired by Medtronic on Jan. 8.